Business Acumen and Financial Expertise
Please check back later for more content.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche
2
Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program
3
FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease
4
MFN Is an Offer Pharma Can’t Refuse
5